APM
RARE icon

Avidity Partners Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Avidity Partners Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-154,000
Closed -$5.6M – 59
2025
Q2 		$5.6M Sell
154,000
-168,100
-52% -$6.06M 1.12% 33
2025
Q1 		$11.7M Sell
322,100
-29,900
-8% -$1.24M 2.22% 13
2024
Q4 		$14.8M Sell
352,000
-400,000
-53% -$19.8M 1.45% 30
2024
Q3 		$41.8M Sell
752,000
-208,000
-22% -$10.6M 2.13% 17
2024
Q2 		$39.5M Buy
960,000
+26,500
+3% +$1.13M 1.68% 22
2024
Q1 		$43.6M Buy
933,500
+89,000
+11% +$4.2M 1.41% 23
2023
Q4 		$40.4M Buy
844,500
+300,500
+55% +$11.6M 1.47% 32
2023
Q3 		$19.4M Sell
544,000
-356,700
-40% -$14.1M 0.78% 48
2023
Q2 		$41.5M Sell
900,700
-1,226,200
-58% -$56.9M 1.45% 28
2023
Q1 		$85.3M Sell
2,126,900
-863,100
-29% -$37M 2.83% 9
2022
Q4 		$139M Buy
2,990,000
+938,400
+46% +$36.9M 3% 10
2022
Q3 		$85M Buy
2,051,600
+572,100
+39% +$29.4M 1.73% 23
2022
Q2 		$88.3M Buy
1,479,500
+610,500
+70% +$37.6M 2.03% 23
2022
Q1 		$63.1M Buy
869,000
+169,000
+24% +$11.8M 1.31% 24
2021
Q4 		$58.9M Buy
700,000
+245,000
+54% +$19.9M 1.25% 30
2021
Q3 		$41M Buy
+455,000
New +$41.1M 0.91% 37

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Avidity Partners Management's RARE Position: Q3 2025 in Review

Avidity Partners Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 154,000 shares — an estimated $5.6M sold.

Avidity Partners Management first reported a position in RARE in Q3 2021 and held it in 16 quarters. The position peaked at $139M in Q4 2022. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Avidity Partners Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Avidity Partners Management sold 154,000 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $5.6M.
  • Avidity Partners Management first reported a position in Ultragenyx Pharmaceutical in Q3 2021 and held it in 16 quarters.
  • Avidity Partners Management's Ultragenyx Pharmaceutical position peaked at $139M in Q4 2022.
  • 302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Avidity Partners Management's 13F filing for Q3 2025, filed 14 Nov 2025.